At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis: Final Results
In Brief
An observational study evaluating omeprazole for Gastroesophageal Reflux Disease (GERD) and Chronic Laryngitis. Completed, enrolled 36 participants across 1 site.
Detailed Summary
* Saliva plays a key role in the homeostasis of the digestive tract * The reflux of gastroesophageal contents may cause damage to the esophageal, laryngeal and pharyngeal mucosas * There seems to be no correlation between the severity of reflux episodes and the intensity of inflammatory changes, suggesting individual protective mechanisms to refluxate exposure * Inorganic and Organic Salivary changes have been associated to Gastroesophageal Reflux Disease (GERD) and its supraesophageal manifestations, especially reflux laryngitis (Laryngopharyngeal Reflux- LPR) * Decreased salivary Epidermal Growth factor (EGF) concentrations have been found in patients with GERD and LPR, but it is unclear if these are primary or secondary to the disease. * Hypothesis: The decreased salivary EGF concentrations in patients with reflux laryngitis is primary and therefore would not change after treatment and control of the disease
Study Details
Timeline
Interventions
omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes